Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04705415 · ClinicalTrials.gov registry record · Phase 1

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

A Phase 1 study, sponsored by NeuroBo Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target

NCT04705415 is a Phase 1 study that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 54 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04705415, a Phase 1 study, has completed, sponsored by NeuroBo Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target

Study Summary

A single and multiple ascending dose study of ANA001 in healthy adults to assess the safety and pharmacokinetics

Interventions

  • DRUG Placebo
  • DRUG Niclosamide

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2020-11-17
Est. Completion 2022-10-28
Phase Phase 1

Sponsor

NeuroBo Pharmaceuticals

8 total trials

What the Registry Record Tells You About NCT04705415

The ClinicalTrials.gov registry entry for NCT04705415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04705415 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04705415 about?

NCT04705415 is a clinical study titled "A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers". A single and multiple ascending dose study of ANA001 in healthy adults to assess the safety and pharmacokinetics

What is the current status of trial NCT04705415?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2020-11-17. Estimated completion is 2022-10-28.

What interventions are being tested in trial NCT04705415?

The interventions under investigation include: Placebo (DRUG), Niclosamide (DRUG).

Who is sponsoring clinical trial NCT04705415?

This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.